These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 18765823)

  • 1. HER receptor signaling confers resistance to the insulin-like growth factor-I receptor inhibitor, BMS-536924.
    Haluska P; Carboni JM; TenEyck C; Attar RM; Hou X; Yu C; Sagar M; Wong TW; Gottardis MM; Erlichman C
    Mol Cancer Ther; 2008 Sep; 7(9):2589-98. PubMed ID: 18765823
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417.
    Haluska P; Carboni JM; Loegering DA; Lee FY; Wittman M; Saulnier MG; Frennesson DB; Kalli KR; Conover CA; Attar RM; Kaufmann SH; Gottardis M; Erlichman C
    Cancer Res; 2006 Jan; 66(1):362-71. PubMed ID: 16397250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors.
    Huang F; Greer A; Hurlburt W; Han X; Hafezi R; Wittenberg GM; Reeves K; Chen J; Robinson D; Li A; Lee FY; Gottardis MM; Clark E; Helman L; Attar RM; Dongre A; Carboni JM
    Cancer Res; 2009 Jan; 69(1):161-70. PubMed ID: 19117999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
    Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
    Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug efflux by breast cancer resistance protein is a mechanism of resistance to the benzimidazole insulin-like growth factor receptor/insulin receptor inhibitor, BMS-536924.
    Hou X; Huang F; Carboni JM; Flatten K; Asmann YW; Ten Eyck C; Nakanishi T; Tibodeau JD; Ross DD; Gottardis MM; Erlichman C; Kaufmann SH; Haluska P
    Mol Cancer Ther; 2011 Jan; 10(1):117-25. PubMed ID: 21220496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin receptor (IR) pathway hyperactivity in IGF-IR null cells and suppression of downstream growth signaling using the dual IGF-IR/IR inhibitor, BMS-754807.
    Dinchuk JE; Cao C; Huang F; Reeves KA; Wang J; Myers F; Cantor GH; Zhou X; Attar RM; Gottardis M; Carboni JM
    Endocrinology; 2010 Sep; 151(9):4123-32. PubMed ID: 20610571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling.
    Warshamana-Greene GS; Litz J; Buchdunger E; Hofmann F; García-Echeverría C; Krystal GW
    Mol Cancer Ther; 2004 May; 3(5):527-35. PubMed ID: 15141010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BMS-754807 is cytotoxic to non-small cell lung cancer cells and enhances the effects of platinum chemotherapeutics in the human lung cancer cell line A549.
    Franks SE; Jones RA; Briah R; Murray P; Moorehead RA
    BMC Res Notes; 2016 Mar; 9():134. PubMed ID: 26928578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo.
    Ji QS; Mulvihill MJ; Rosenfeld-Franklin M; Cooke A; Feng L; Mak G; O'Connor M; Yao Y; Pirritt C; Buck E; Eyzaguirre A; Arnold LD; Gibson NW; Pachter JA
    Mol Cancer Ther; 2007 Aug; 6(8):2158-67. PubMed ID: 17671083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways.
    Dayyani F; Parikh NU; Varkaris AS; Song JH; Moorthy S; Chatterji T; Maity SN; Wolfe AR; Carboni JM; Gottardis MM; Logothetis CJ; Gallick GE
    PLoS One; 2012; 7(12):e51189. PubMed ID: 23300537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy.
    Litzenburger BC; Creighton CJ; Tsimelzon A; Chan BT; Hilsenbeck SG; Wang T; Carboni JM; Gottardis MM; Huang F; Chang JC; Lewis MT; Rimawi MF; Lee AV
    Clin Cancer Res; 2011 Apr; 17(8):2314-27. PubMed ID: 21177763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like growth factor-1 receptor and ErbB kinase inhibitor combinations block proliferation and induce apoptosis through cyclin D1 reduction and Bax activation.
    Wilsbacher JL; Zhang Q; Tucker LA; Hubbard RD; Sheppard GS; Bamaung NY; Fidanze SD; Wang GT; Hu X; Davidsen SK; Bell RL; Wang J
    J Biol Chem; 2008 Aug; 283(35):23721-30. PubMed ID: 18559346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells.
    Nahta R; Yuan LX; Zhang B; Kobayashi R; Esteva FJ
    Cancer Res; 2005 Dec; 65(23):11118-28. PubMed ID: 16322262
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-like growth factor receptor expression is associated with aggressive phenotypes and has therapeutic activity in biliary tract cancers.
    Ohashi H; Adachi Y; Yamamoto H; Taniguchi H; Nosho K; Suzuki H; Arimura Y; Imai K; Carbone DP; Shinomura Y
    Cancer Sci; 2012 Feb; 103(2):252-61. PubMed ID: 22044563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
    Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
    Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.
    Ma Y; Tang N; Thompson RC; Mobley BC; Clark SW; Sarkaria JN; Wang J
    Clin Cancer Res; 2016 Apr; 22(7):1767-76. PubMed ID: 26561558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells.
    Balañá ME; Labriola L; Salatino M; Movsichoff F; Peters G; Charreau EH; Elizalde PV
    Oncogene; 2001 Jan; 20(1):34-47. PubMed ID: 11244498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of insulin receptor isoform A and insulin-like growth factor-1 receptor in human acute myelogenous leukemia: effect of the dual-receptor inhibitor BMS-536924 in vitro.
    Wahner Hendrickson AE; Haluska P; Schneider PA; Loegering DA; Peterson KL; Attar R; Smith BD; Erlichman C; Gottardis M; Karp JE; Carboni JM; Kaufmann SH
    Cancer Res; 2009 Oct; 69(19):7635-43. PubMed ID: 19789352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
    Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
    Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human pancreatic cancer stem cells are sensitive to dual inhibition of IGF-IR and ErbB receptors.
    Urtasun N; Vidal-Pla A; Pérez-Torras S; Mazo A
    BMC Cancer; 2015 Apr; 15():223. PubMed ID: 25886138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.